<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443351</url>
  </required_header>
  <id_info>
    <org_study_id>TPO-SJ-227</org_study_id>
    <nct_id>NCT01443351</nct_id>
  </id_info>
  <brief_title>Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)</brief_title>
  <official_title>Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombopoietin Receptor Agonists (TPO-ra) are novel treatment modalities for patients with
      refractory Primary Immune Thrombocytopenia (ITP), but only few data are available for
      long-term effects of these drugs. In this observational study, effects and adverse effects
      including evaluation of bone marrow biopsies done at fixed intervals will be recorded from
      ITP patients treated with TPO-ra. For some patients, blood samples will be collected for
      research use.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    failure to recruit patients
  </why_stopped>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with sustained response at 6 months follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>Response is defined as platelet count &gt; 30.000 mio/L and no bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yearly response rates</measure>
    <time_frame>5 years</time_frame>
    <description>Number of patients with response to treatment at 1, 2, 3, 4, and 5-year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of relapse</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of splenectomy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of reticulin fibrosis in bone marrow biopsies</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>ITP patients</arm_group_label>
    <description>Patients with refractory ITP eligible for treatment with TPO-ra</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples will be collected, seru, plasma and mononuclear cells will be stored in a
      biobank for further research use
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patinets will be selected from Departments of Hematology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with ITP

          -  platelet counts &lt; 25 x10*9/L or &lt; 50 x10*9/L with bleeding symptoms

          -  meets criteria for treatment with TPO-ra

          -  Females must use contraceptives when applicable for at least three months before
             inclusion

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Former thromboembolic events excluding one incidence of deep venous thrombosis as
             complication to surgery or pregnancy or one incidence of cerebral embolism as
             complication to atrial fibrillation

          -  Liver insufficiency (for eltrombopag only)

          -  TPO-ra contraindications (e.g. allergy)

          -  TPO-ra treatments less than 6 months prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Hasselbalch, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Copenhagen University Hospital Roskilde</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Frederiksen, Dr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sif Gudbrandsdottir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital Roskilde</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 13, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Sif Gudbrandsdottir</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ITP</keyword>
  <keyword>romiplostim</keyword>
  <keyword>eltrombopag</keyword>
  <keyword>bone marrow fibrosis</keyword>
  <keyword>long-term safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

